



STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

SUITE 600

1100 NEW YORK AVENUE, N.W.

WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540; (202) 371-6566

GP-1808
1651
\$

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC K. STEFFE
MICHAEL Q. LEE

JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
STEVEN R. LUDWIG
MICHAEL V. MESSINGER
JUDITH U. KIM*
KEITH KIND
TIMOTHY J. SHEA, JR.
DONALD R. MCPHAIL
PATRICK E. GARRETT
BARBARA A. PARVIS
MICHAEL A. RAHMAN*

STEPHEN G. WHITESIDE*
NOEL B. WHITLEY*
JEFFREY T. HELVEY*
RICHARD A. DUNNING, JR.
KIMBERLIN M. TOOHEY
RALPH P. ALBRECHT
HEIDI L. KRAUS*
JEFFREY R. KURIN*
CARL B. MASSEY, JR.*
RAYMOND MILLIEN*
PATRICK D. O'BRIEN*
BRIAN S. ROSENBLUM*

DONALD J. FEATHERSTONE**
LAWRENCE B. BUGAISKY**
KAREN R. MARKOWICZ**
GRANT E. REED**
VICTOR E. JOHNSON**
SERGE SIRA**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

WRITER'S DIRECT NUMBER:


(202) 371-2653

INTERNET ADDRESS:

April 15, 1998

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application
Appl. No. 08/896,053
Filed: July 17, 1997
For: **Method of Inducing Vasodilation and Treating Pulmonary Hypertension Using Adenoviral-Mediated Transfer of the Nitric Oxide Synthase Gene**
Inventor(s): JANSSENS *et al.*
Our Ref: 0609.4280001/JAG/RCM



Sir:

Transmitted herewith for appropriate action is the following:

1. Transmittal Letter (*in duplicate*);
2. Petition for Extension of Time under 37 C.F.R. § 1.136(a);
3. Copy of returned postcard and our Check No. 21574 acknowledging the filing and payment of the four-month extension of time fee; and
4. Return postcard.

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Assistant Commissioner for Patents

April 15, 1998

Page 2

It is respectfully requested that the attached postcard be stamped with the filing date of these documents and returned to our courier.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. If extensions of time under 37 C.F.R. § 1.136 other than those otherwise provided for herewith are required to prevent abandonment of the present patent application, then such extensions of time are hereby petitioned, and any fees therefor are hereby authorized to be charged to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert C. Millonig
Attorney for Applicants
Registration No. 34,395

Enclosures

P:\USERS\BOBM\0609\4280001\EXT.tml

STERNE, KESSLER, GOLDSTEIN & FOX PLLC
ATTORNEYS AT LAW
GOVERNMENT FEES ACCT.
1100 NEW YORK AVE. NW, SUITE 600
WASHINGTON, D.C. 20005

REMITTANCE ADVICE					

21574

15-122
540

PAY -

THE SUM 2430 DOLLARS

DOLLARS

DATE	TO THE ORDER OF	CHECK AMOUNT
7/13/97	COMM. OF PATENTS & TRADEMARKS	2430.00

DOMINION
BANK



WASHINGTON, D.C. 20005

Screened & 7e

MP

⑈021574⑈ ⑆054001220⑆ 76 50030798⑈

Attn: Box Patent Application

Applicant: JANSSENS *et al.*

Due Date: April 15, 1998

Application No.: 08/896,053

Art Unit: 1808


Filed: July 17, 1997

Examiner: Unknown

Docket: 0609.4280001

Atty: JAG/RCM

For: Method of Inducing Vasodilation and Treating Pulmonary Hypertension Using Adenoviral-Mediated Transduction of the Nitric Oxide Synthase Gene



When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. Transmittal Letter (*in duplicate*);
2. Copy of the Notice to file Missing Parts of Application-Filing Date Granted mailed October 15, 1997;
3. Original Declaration, executed by the inventors Stefan Janssens & Désiré Collen;
4. Original Declaration, executed by the inventor, Kenneth D. Bloch;
5. An original Power of Attorney from Multiple Assignees executed by officials from The General Hospital Corporation and Leuven Research Development, V.Z.W.;
6. Two Assignee Certificates Under 37 C.F.R. § 3.73(b), one from The General Hospital Corporation and the other from Leuven Research Development, V.Z.W.; with copy of Assignment attached to each;
7. Preliminary Amendment and Submission of Sequence Listing including hard copy and computer readable for of Sequence Listing;
8. Return postcard; and
9. Our Check No. 21574 \$2,430.00 to cover: \$790.00 Filing Fee for Patent Application (37 C.F.R. § 1.16)
\$130.00 Surcharge for late filing of Declaration (37 C.F.R. § 1.16)
\$1510.00 Petition for Extension fees under 37 C.F.R. § 1.136 (four months)